Obstructive sleep apnoea (OSA) and hyperaldosteronism are very common in subjects with resistant hypertension. We hypothesized that aldosterone-mediated chronic fluid retention may influence OSA severity in patients with resistant hypertension. We tested this in an open-label evaluation by assessing the changes in the severity of OSA in patients with resistant hypertension after treatment with spironolactone. Subjects with resistant hypertension (clinical blood pressure (BP) X140/ 90 mm Hg on X3 antihypertensive medications, including a thiazide diuretic and OSA (defined as an apnoeahypopnoea index (AHI) X15) had full diagnostic, polysomnography before and 8 weeks after spironolactone (25-50 mg a day) was added to their ongoing antihypertensive therapy. In all, 12 patients (mean age 56 years and body mass index 36.8 kg m -2 ) were evaluated. After treatment with spironolactone, the AHI (39.8±19.5 vs 22.0 ± 6.8 events/h; Po0.05) and hypoxic index (13.6 ± 10.8 vs 6.7 ± 6.6 events/h; Po0.05), weight and clinic and ambulatory BP were significantly reduced. Plasma renin activity (PRA) and serum creatinine were significantly higher. This study provides preliminary evidence that treatment with a mineralocorticoid receptor antagonist substantially reduces the severity of OSA. If confirmed in a randomized assessment, it will support aldosterone-mediated chronic fluid retention as an important mediator of OSA severity in patients with resistant hypertension.
Obstructive sleep apnoea (OSA) and hyperaldosteronism are very common in subjects with resistant hypertension. We hypothesized that aldosterone-mediated chronic fluid retention may influence OSA severity in patients with resistant hypertension. We tested this in an open-label evaluation by assessing the changes in the severity of OSA in patients with resistant hypertension after treatment with spironolactone. Subjects with resistant hypertension (clinical blood pressure (BP) X140/ 90 mm Hg on X3 antihypertensive medications, including a thiazide diuretic and OSA (defined as an apnoeahypopnoea index (AHI) X15) had full diagnostic, polysomnography before and 8 weeks after spironolactone (25-50 mg a day) was added to their ongoing antihypertensive therapy. In all, 12 patients (mean age 56 years and body mass index 36.8 kg m -2
Introduction
Obstructive sleep apnoea (OSA) is very common in patients with resistant hypertension. 1, 2 In a prospective evaluation of 42 subjects with resistant hypertension, Logan et al. 1 found that 83% of the subjects had unsuspected OSA based on an apnoea-hypopnoea index (AHI) of X10 events per hour. The pathophysiological mechanism of this high prevalence of OSA in patients with resistant hypertension has not been explained.
We and others have identified primary aldosteronism as being common in patients with resistant hypertension, with a prevalence of approximately 20%. [3] [4] [5] [6] Aldosterone, through its classical effects at the level of the distal nephron, induces sodium and fluid retention. Beyond hyperaldosteronism, we reported that resistant hypertension is in general characterized by significant fluid retention, even in subjects without demonstrable aldosterone excess. This fluid retention persists in spite of long-term thiazide diuretic use. 7 Recent studies link acute changes in intravascular volume with upper airway resistance and OSA severity. 8, 9 These studies suggest that peripharyngeal fluid accumulation predisposes to upper airway obstruction, particularly when in the supine position, as with sleep. In finding both a high prevalence of OSA and broad evidence of intravascular volume overload in patients with resistant hypertension, we hypothesized that chronic fluid retention may underlie the high prevalence of OSA in patients with resistant hypertension. To test this hypothesis, we administered spironolactone for 8 weeks in patients with resistant hypertension and OSA and assessed changes in OSA variables.
Methods

Subjects
Consecutive subjects who were referred to the Hypertension Clinic of the University of Alabama at Birmingham for resistant hypertension (defined as uncontrolled hypertension at two clinic visits, in spite of use of three antihypertensive medications including a thiazide diuretic at pharmacologically effective doses) were enroled in the study. Secondary causes of hypertension other than hyperaldosteronism, including renovascular hypertension, pheochromocytoma or Cushing's syndrome, were excluded by laboratory analysis and/or radiological imaging as clinically indicated. Subjects with current use of continuous positive airway pressure for OSA or with recent myocardial infarction or stroke (within 6 months before study), congestive heart failure, chronic kidney disease (creatinine clearance o60 ml min ) and long-term use of systemic steroids were excluded. This study was approved by the institutional review board of the University of Alabama at Birmingham, and all subjects provided a written consent before study enrolment.
Clinical evaluation
Seated clinic blood pressure (BP) was measured using a sphygmomanometer with an appropriately sized cuff at each clinic visit after 5 min of rest. The mean of two readings was recorded. The 24-h ambulatory blood pressure measurements were recorded using Suntech monitor (Suntech Medical, Morrisville, NC, USA). The monitor recorded systolic and diastolic BP every 20 min during the daytime (0600-2200 hours) and every 30 min at night (2200-0600 hours). The ambulatory data were included in the analysis if the monitoring period was 420 h and there were no periods of 42 h without measurements.
Biochemical evaluation
Biochemical evaluation was performed for all subjects on an outpatient basis. Early morning ambulatory plasma aldosterone concentration, plasma renin activity (PRA), brain natriuretic peptide, serum potassium, serum creatinine and 24-h urinary collection for aldosterone, sodium and creatinine were obtained at baseline during consumption of the subject's routine diet. Antihypertensive treatment was maintained constant for at least 4 weeks before baseline evaluation. Potassium-sparing diuretics, including spironolactone, eplerenone or amiloride, were discontinued at least 6 weeks before the study. Serum potassium was corrected to above 3.5 mEq l -1 before biochemical evaluation.
Polysomnography
All subjects underwent full-night, attended, diagnostic polysomnography. Polysomnographic evaluation included airflow monitoring with thermocouple and/ or nasal pressure, respiratory effort using piezo belts at the chest and abdominal positions, oxygen saturation using pulse oximetry, heart rate using single-lead electrocardiogram, electroencephalogram (C4-A1, C3-A2, O2-A1 and O1-A2), submental and tibial electromyograms and bilateral electro-oculograms. Apnoea was defined as cessation in airflow for X10 s. Hypopnoea was defined as a reduction in the amplitude of airflow of at least 30% for X10 s, followed by either decrease in oxygen saturation of 4% or signs of physiologic arousal (at least 3 s of a-activity). The AHI was calculated as the total number of apnoeas and hypopnoeas divided by the hours of sleep. Sleep was staged according to the criteria of Rechtschaffen and Kales. 10 The percentage of sleep time spent with an oxygen saturation of o90%, the hypoxic index, was also determined. Supine AHI (AHI during supine position) and AHI during rapid eye movement sleep were also determined and compared between baseline and followup studies to control for the variability in position and duration of various stages of sleep (OSA tends to be more severe during rapid eye movement supine sleep). Sleep stage and nocturnal events were continuously supervised by a registered polysomnographic technologist. The scoring of all studies was confirmed by an American Board of Sleep Medicine Diplomat who was blinded to whether studies were baseline or follow-up evaluations.
Treatment and follow-up
After baseline evaluation, the subjects with moderate-severe OSA (AHI X15 events per hour) were started on spironolactone 25 mg once daily and force-titrated to 50 mg once daily at 4 weeks. Other antihypertensive medications were discontinued if needed because of low BP (o110/70 mm Hg and/or symptoms). Withdrawn medications were limited to centrally acting agents or vasodilators followed by b-blockers and calcium channel blockers such that all patients remained on their baseline thiazide diuretic and renin angiotensin system blocker (angiotensinconverting enzyme inhibitor and/or angiotensin receptor blocker) throughout the treatment period. Clinic BP, ambulatory BP, overnight polysomnography and biochemical evaluation for serum potassium, creatinine, brain natriuretic peptide and PRA were repeated after 8 weeks of spironolactone intervention.
Analysis
Values are expressed as mean ± s.d. Owing to the small sample size, the differences between baseline and follow-up measures were compared using Wilcoxon's signed-rank test. As measures within subjects are highly correlated, no adjustments were made for multiple testing. The P-values are provided for descriptive purposes and Po0.05 was deemed as meaningful change. Data analysis was carried out using statistical software (JMP, version 6; SAS Institute Inc., Cary, NC, USA).
Results
In all, 12 subjects, including 58% males and 50% whites, were evaluated (Table 1) . They were receiving an average of 4.3 antihypertensive medications including, a thiazide diuretic and either an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker in all subjects. After 8 weeks of addition of spironolactone, the body weight, clinic systolic and diastolic BP, 24-h ambulatory systolic BP, daytime systolic BP, and night time systolic and night time diastolic BP were all significantly decreased (Table 2) . Ambulatory daytime and 24-h diastolic BP tended to be lower but did not reach statistical significance. Severity of OSA assessed by AHI, hypoxic index, supine AHI and AHI during rapid eye movement sleep was significantly lower with spironolactone treatment (Figure 1 ). Reduction in total AHI, supine AHI and AHI during rapid eye movement sleep was noted in all 12 subjects irrespective of aldosterone status. Serum creatinine and PRA were significantly increased with treatment. In addition, neck circumference, and brain natriuretic peptide tended to be lower and serum potassium tended to be higher but did not achieve statistical significance (Table 2) .
Discussion
This is the first study showing that treatment with a mineralocorticoid receptor antagonist substantially reduces OSA severity in patients with resistant hypertension. Overall, the OSA severity, as indexed by the AHI and hypoxic index, was reduced by almost 50%. This benefit occurred in the setting of increased diuresis, suggesting that the effect may be secondary to decreases in pharyngeal oedema and consequent reductions in upper airway resistance. These results provide preliminary evidence linking aldosterone-induced fluid retention to severity of OSA and if confirmed in a randomized comparison, would explain in part, the high prevalence of OSA in patients with resistant hypertension. Obstructive sleep apnoea is extraordinarily common in patients with resistant hypertension. In two separate prospective evaluations, OSA was found to have a prevalence of 80-85% in subjects with resistant hypertension. 1, 2 The interaction between OSA and hypertension is not clear. Studies have implicated systemic inflammation, oxidative stress, endogenous vasoactive factors, endothelial dysfunction, increased sympathetic activation and metabolic dysregulation as potential mechanisms of hypertension related to OSA. 11 Several studies have shown that continuous positive airway pressure treatment in patients with OSA reduces sympathetic activity, 12 decreases production of free radicals and other inflammatory products 13 and reverses the endothelial dysfunction.
14 However, only modest improvement in BP has been shown with continuous positive airway pressure treatment. 15 Primary aldosteronism has also been found to be very common in patients with resistant hypertension. In a prospective evaluation carried out by our laboratory, 20% of subjects with resistant hypertension were confirmed to have primary aldosteronism. 3 A similarly high prevalence of primary aldosteronism in subjects with resistant hypertension has been confirmed by other laboratories. [4] [5] [6] Recognizing that OSA and primary aldosteronism are both prevalent in patients with resistant hypertension, we hypothesized that the two entities may be causally related, that is, one contributing to the other. Two earlier studies provided preliminary support for the hypothesis that primary aldosteronism contributes to development and/or severity of OSA. 2, 16 In the first study, 16 we reported that the risk of having OSA, based on the Berlin Questionnaire, which is a validated survey for identifying subjects at risk of having OSA, 17 was significantly higher in subjects with resistant hypertension and primary aldosteronism when compared with subjects without evidence of aldosterone excess. In the second study, 2 we reported that aldosterone levels positively correlated with OSA severity in patients with resistant hypertension, but not in control patients with similar age, body mass index and OSA severity but without resistant hypertension. Combined, these two studies suggested that in subjects with resistant hypertension, aldosterone may contribute to OSA severity.
In this study, we directly tested this hypothesis by evaluating the effects of mineralocorticoid blockade on OSA severity in subjects with resistant hypertension. After 8 weeks of treatment, OSA severity was substantially reduced. These results provide support for a possible role of aldosterone in contributing to OSA risk in patients with resistant hypertension. This reduction in OSA severity was associated with an evidence of more effective diuresis, as indicated by a significant increase in PRA and serum creatinine, decrease in body weight and a tendency toward lower plasma brain natriuretic peptide, consistent with reduction in intravascular volume. Although not tested in this evaluation, we speculate that improved diuresis with accompanying reduction in peripharyngeal oedema and improvement in upper airway resistance represents the pathophysiological mechanism of the strong association between aldosterone excess and OSA.
Support for peripharyngeal oedema as a cause of upper airway obstruction is provided by acute studies relating changes in intravascular volume to upper airway resistance and severity of OSA. 8, 9 In the first case, acute increases in venous return with application of lower body positive pressure resulted in increases in neck circumference and upper airway resistance in healthy volunteers. 8 This suggests that increases in venous pressure and fluid accumulation in the neck predisposes to pharyngeal obstruction. In the second case, acute diuresis, including spironolactone, improved severity of OSA in patients who were admitted with exacerbation of congestive heart failure secondary to diastolic dysfunction. 9 This improvement in OSA occurred in association with reduction in oropharyngeal cross-sectional area (as indexed by acoustic pharyngometry), also suggesting a role of peripharyngeal fluid accumulation. Fluid overload as a cause of OSA is further supported by studies showing improvements in OSA after dialysis in patients with end-stage renal disease. 18, 19 The above studies suggest that volume overload can acutely worsen OSA by increasing pharyngeal obstruction with peripharyngeal fluid accumulation. The results of this study extend these observations by suggesting that similar effects may occur chronically in patients with resistant hypertension secondary to aldosterone-induced fluid retention. We hypothesize that spironolactone, by reversing chronic fluid retention, reduces peripharyngeal fluid accumulation and thereby lowers the risk of upper airway obstruction. Importantly, in the current analysis, the benefit of spironolactone occurred when added to chronic thiazide diuretic use. This suggests that thaizides, at least at conventional doses, are not sufficient to overcome this chronic fluid retention. It may be that more effective diuresis with use of higher doses of the thiazide diuretic or perhaps addition of a loop diuretic would also facilitate comparable improvements in OSA, but this needs further evaluation in comparison to spironolactone. This study is strengthened by its prospective design, use of full-night diagnostic polysomnograms to quantify OSA severity and blinding of the scoring physician to study status. Important study limitations include evaluation of a relatively small number of subjects and lack of an active comparator. A comparison with an active control, such as another class of diuretic, will be necessary to establish that the effects are unique to mineralocorticoid receptor blockade.
Whether the findings in this study are limited to patients with resistant hypertension or could be extended to a more general hypertensive population with OSA remains to be established. Resistant hypertension is known to be characterized by increased aldosterone levels and chronic fluid retention, 7 and hence the effects of mineralocorticoid blockade are likely to be most pronounced in this subgroup of hypertensive patients. However, primary aldosteronism is being recognized as being generally much more common than thought historically, 20, 21 and hence its role in contributing to OSA may not be limited to just patients with resistant hypertension.
Clinical implications
The current findings implicate aldosterone-induced fluid retention as an important cause of OSA in patients with resistant hypertension. If confirmed, these results would explain at least in part the high prevalence of OSA in patients with resistant hypertension. These results emphasize the importance of screening for OSA in patients with resistant hypertension and highlight the potential benefit of spironolactone as an adjunct to continuous positive airway pressure in this group of patients. In addition, it is well recognized that OSA and primary aldosteronism are separately associated with increased risk of cardiovascular disease, including myocardial infarction, stroke, arrhythmias and congestive heart failure. [22] [23] [24] The current findings provide explanation of these shared risks in suggesting that aldosterone excess may predispose to the development of OSA.
What is known about this topic K Obstructive sleep apnoea (OSA) and primary aldosteronism are very common in patients with resistant hypertension. K The pathophysiological mechanism of this high prevalence of OSA in patients with resistant hypertension has not been explained. K Beyond hyperaldosteronism, we reported that resistant hypertension is in general characterized by significant fluid retention, even in subjects without demonstrable aldosterone excess. This fluid retention persists in spite of long-term thiazide diuretic use.
What this study adds K This is the first study showing that treatment with a mineralocorticoid receptor antagonist substantially reduces OSA severity in patients with resistant hypertension. K This study provides preliminary evidence linking aldosterone-induced fluid retention with severity of OSA, and if confirmed in a randomized comparison, it would explain in part the high prevalence of OSA in patients with resistant hypertension. K It is well recognized that OSA and primary aldosteronism are separately associated with increased risk of cardiovascular disease, including myocardial infarction, stroke, arrhythmias and congestive heart failure. The current findings provide explanation of these shared risks in suggesting that aldosterone excess may predispose to the development of OSA.
